Evidence map›Paper›PMID 41047813›Full record

ArticleAngewandte Chemie (International ed. in English)2025

A Triple Threat Against Ovarian Cancer: Os(II)-Pt(IV)-Ceritinib Conjugates for Photodynamic Therapy, Chemotherapy, and Immunogenic Cell Death Induction.

Marta Redrado, Sourav Acharya, Pierre Mesdom, Tomer Babu, James W Southwell, Laiane S Oliveira, Samia Hidalgo, Philippe Arnoux, Céline Frochot, Dan Gibson and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Marta Redrado *Chimie ParisTech, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, PSL University, CNRS, Paris, 75005, France.
Sourav Acharya *Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, 91120, Israel.
Pierre MesdomChimie ParisTech, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, PSL University, CNRS, Paris, 75005, France.
Tomer BabuInstitute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, 91120, Israel.
James W SouthwellChimie ParisTech, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, PSL University, CNRS, Paris, 75005, France.
Laiane S OliveiraChimie ParisTech, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, PSL University, CNRS, Paris, 75005, France.
Samia HidalgoInstitut de Physique du Globe de Paris, Biogéochimie à l'Anthropocène des Eléments et Contaminants Emergents, Paris, 75005, France.
Philippe ArnouxUniversité de Lorraine, CNRS, LRGP, Nancy, F-54000, France.
Céline FrochotUniversité de Lorraine, CNRS, LRGP, Nancy, F-54000, France.
Dan GibsonInstitute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, 91120, Israel.
Gilles GasserChimie ParisTech, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, PSL University, CNRS, Paris, 75005, France.ORCID 0000-0002-4244-5097

Funding

ERC GA 101113026Fondation pour la Recherche Médicale SPF202309017545Israel Science Foundation 1182/23SESAME 12015908
6 · The paper itself

Abstract

Metal-based anticancer agents offer unique opportunities to integrate multiple therapeutic modalities within a single molecular framework. Herein, we present the first Osmium(II)-Platinum(IV)-Ceritinib conjugate (Os-Pt-Cer) that synergistically combines photodynamic therapy (PDT), chemotherapy, and immunotherapy via immunogenic cell death (ICD) induction. This heterobimetallic complex features a photoactive osmium(II) polypyridyl core, a platinum(IV) prodrug derived from oxaliplatin, and the kinase inhibitor ceritinib as an axial ligand. Upon deep-red irradiation (λ = 740 nm), the conjugate exhibits potent antiproliferative activity in ovarian 2D cancer cells and 3D tumour spheroids, with IC

Indexed as

Antineoplastic AgentsCoordination ComplexesImmunogenic Cell DeathOsmiumOvarian NeoplasmsPhotochemotherapyPlatinumPyrimidinesCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorFemaleHumansAntineoplastic AgentsCoordination ComplexesOsmiumPlatinumPyrimidinesBioinorganic chemistryMedicinal inorganic chemistryMetals in medicine: osmiumPhotodynamic therapyPlatinum prodrugs

Identifiers

PMID41047813
PMCPMC12668304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.